✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Alivus Life Sciences Ltd.

ALIVUS

Market Cap
₹12,586 Cr.
P/E
28.50

Alivus Life Sciences Ltd.

  • Alivus Life Sciences
  • Neuland Laboratories
  • IOL Chem & Pharma
  • TJI Pharma - API & CRAMS
FAQs on Alivus Life Sciences Ltd. Shareprice

Alivus Life Sciences has given better returns compared to its competitors.
Alivus Life Sciences has grown at ~48.98% over the last 2yrs while peers have grown at a median rate of 44.02%

Yes, Alivus Life Sciences is expensive.
Latest PE of Alivus Life Sciences is 28.39, while 3 year average PE is 19.17.
Also latest EV/EBITDA of Alivus Life Sciences is 19.33 while 3yr average is 12.32.

View FAQ's On Business
Growth Table
  • Alivus Life Sciences Ltd.
  • Neuland Laboratories
  • IOL Chem & Pharma
Balance Sheet
  • Alivus Life Sciences Ltd.
  • Neuland Laboratories
  • IOL Chem & Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Alivus Life Sciences Ltd.
  • Neuland Laboratories
  • IOL Chem & Pharma
Cash Flow
  • Alivus Life Sciences Ltd.
  • Neuland Laboratories
  • IOL Chem & Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Alivus Life Sciences Ltd.
  • Neuland Laboratories
  • IOL Chem & Pharma
Quarterly Results
  • Alivus Life Sciences Ltd.
  • Neuland Laboratories
  • IOL Chem & Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Alivus Life Sciences Ltd. Financials

Balance sheet of Alivus Life Sciences is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Alivus Life Sciences is increasing.
Latest debt of Alivus Life Sciences is -₹446.29 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹603.15 Crs.

The profit is oscillating.
The profit of Alivus Life Sciences is ₹442 Crs for TTM, ₹471 Crs for Mar 2024 and ₹467 Crs for Mar 2023.

The company seems to pay a good stable dividend.
Alivus Life Sciences latest dividend payout ratio is 58.55% and 3yr average dividend payout ratio is 58.37%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech